Context Non Current Liabilities Total from 2010 to 2024

CNTX Stock  USD 1.51  0.05  3.21%   
Context Therapeutics Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total will likely drop to 0.00 in 2024. During the period from 2010 to 2024, Context Therapeutics Non Current Liabilities Total regression line of annual values had r-squared of  0.03 and arithmetic mean of  606,872. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2010-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Context Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Context Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 435.1 K, Selling General Administrative of 9.1 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Context financial statements analysis is a perfect complement when working with Context Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Context Therapeutics Correlation against competitors.
For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

Latest Context Therapeutics' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Context Therapeutics over the last few years. It is Context Therapeutics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Context Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Pretty Stable
   Non Current Liabilities Total   
       Timeline  

Context Non Current Liabilities Total Regression Statistics

Arithmetic Mean606,872
Geometric Mean0.00
Coefficient Of Variation329.86
Mean Deviation964,452
Median126,000
Standard Deviation2,001,858
Sample Variance4T
Range7.8M
R-Value0.16
Mean Square Error4.2T
R-Squared0.03
Significance0.56
Slope72,797
Total Sum of Squares56.1T

Context Non Current Liabilities Total History

2023null
2022 991.41
2021 1826.29
20207.8 M

About Context Therapeutics Financial Statements

Context Therapeutics investors use historical fundamental indicators, such as Context Therapeutics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Context Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.